• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Nanobac Pharmaceuticals Inc. Launches Landmark Study to Explore Heart Disease Properties of Calcifying Nanoparticles

Posted on: Monday, 25 September 2006, 09:00 CDT

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP

- News; "Nanobac"

or "the Company") and Mayo Clinic have reached an agreement to study

whether calcifying nanoparticles, already found in atherosclerotic

plaque, are infectious and contribute to the onset of heart disease.

The identification of the cause of calcification would be a landmark in

heart disease research. While many pathogens have been identified as a

possible cause of calcification in the blood vessels of heart disease

patients, to date, no smoking gun has been identified.

The study, "Nanoparticles and Arterial

Calcification," will be led by Virginia

Miller, Ph.D., with John Lieske, M.D., and Franklin Cockerill, M.D., all

of the Mayo Clinic. It is part of a multi-pronged initiative by

scientists internationally to determine the disease-causing

characteristics of calcifying nanoparticles (CNPs), known as

nanobacteria(1). Each of the researchers has published work in

peer-reviewed journals regarding the potential role of CNPs in heart

disease.

"These Mayo Clinic researchers are among

leading investigators into the disease-related aspects of CNPs,"

said Nanobac Pharmaceuticals' co-chair Dr.

Benedict Maniscalco, himself a cardiologist who has published research

in the field. "We have studied the process of

calcification for years and have documented evidence that will set the

course for this next phase of the research."

The study represents an acceleration of research into the infectious

aspects of calcifying nanoparticles following findings published by

other researchers earlier this year that CNPs provoke stone forming

disease in an animal model. Other concurrent studies are occurring in

China, Finland, and at world-class facilities in Cleveland, Washington

D.C. and at Johnson Space Center in Houston. Those studies are directed

at other disease-causing characteristics of CNPs and potential therapies.

Nanobac and Mayo Clinic have had a general collaboration agreement since

2005.

(1) (Note to editors: the term "Calcifying

Nanoparticle (CNP)" has been adopted in

recently published literature to help distinguish these particles from

bacteria.)

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is a life

sciences company dedicated to the discovery and development of products

and services to improve people's health through the detection and

treatment of Calcifying Nanoparticles (CNPs), otherwise known as

"nanobacteria." The company's pioneering research is establishing the

pathogenic role of CNPs in soft tissue calcification, particularly in

coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing

compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac

manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting

calcifying nanoparticles. IVD products include a line of assays,

proprietary antibodies and reagents for uniquely recognizing CNPs.

Nanobac's BioAnalytical Services works with biopharmaceutical partners

to develop and apply methods for avoiding, detecting, and inactivating

or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For

more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some

statements in periodic press releases and some oral statements of

Nanobac Pharmaceuticals Inc. officials are "Forward-Looking Statements"

within the meaning of the Private Securities Litigation Reform Act of

1995 (the "Act). Forward-Looking statements include statements which are

predictive in nature, which depend upon or refer to future events or

conditions, which include words such as "believes,""anticipates,"

"intends,""plans,""expects," and similar expressions. In addition, any

statements concerning future financial performance (including future

revenues, earnings or growth rates), ongoing business strategies or

prospects, and possible future Nanobac Pharmaceuticals Inc. actions,

which may be provided by management, are also forward-looking statements

as defined by the Act. Forward-Looking statements involve known and

unknown risks, uncertainties, and other factors which may cause the

actual results, performance or achievements of the Company to materially

differ from any future results, performance or achievements expressed or

implied by such forward-looking statements and to vary significantly

from reporting period to reporting period. Although management believes

that the assumptions will, in fact, prove to be correct or that actual

future results will not be different from the expectations expressed in

this report. These statements are not guarantees of future performance

and Nanobac Pharmaceuticals, Inc. has no specific intention to update

these statements.

Source: Business Wire

More News in this Category